Praluent vs Leqvio Side-Effect Profile: A Head-to-Head Clinical Breakdown

How These Two Drugs Actually Work

Praluent (alirocumab) is a fully human monoclonal antibody that binds PCSK9 in the bloodstream and prevents it from degrading LDL receptors on hepatocytes. Leqvio (inclisiran) is a small interfering RNA that silences PCSK9 messenger RNA inside the liver cell before the protein is ever synthesized. The same downstream target, but a completely different point of intervention. That mechanistic split is the single biggest driver of their different side-effect profiles.

Alirocumab: Antibody Binding in Circulation

Because alirocumab circulates as a protein, the immune system can generate anti-drug antibodies (ADAs). In the pooled ODYSSEY program, ADA incidence reached approximately 5.1% of patients, with neutralizing antibodies in about 1.2% [1]. Most ADA-positive patients still achieved meaningful LDL-C lowering, but a small subset experienced attenuated response. Allergic-type reactions, including hypersensitivity and rare angioedema, were reported at a combined rate of about 2.1% versus 1.6% for placebo in clinical trials [2].

Inclisiran: Silencing at the Gene-Expression Level

Inclisiran delivers its siRNA payload to hepatocytes via GalNAc conjugation, a liver-targeting ligand. The drug is almost entirely cleared from plasma within 48 hours of injection, leaving a stable intracellular effect that sustains LDL-C reduction for roughly six months [3]. Because there is no circulating protein to trigger systemic immune recognition, ADA formation has not been a clinically meaningful concern in the ORION program trials. The FDA label for inclisiran does not include a hypersensitivity warning of the same class as alirocumab's label [4].

Injection-Site Reactions: The Shared Side Effect

Both drugs require subcutaneous injection, and injection-site reactions (ISRs) are the most frequently reported adverse event for each. The texture and duration of ISRs differ, which matters for patient selection and counseling.

ISR Data From ODYSSEY OUTCOMES (Alirocumab)

In ODYSSEY OUTCOMES (N=18,924 post-ACS patients), injection-site reactions occurred in 3.8% of alirocumab patients versus 2.1% of placebo patients [5]. Reactions were typically transient, mild to moderate in severity, and resolved without treatment discontinuation in the majority of cases. The trial ran for a median of 2.8 years, giving meaningful long-term ISR incidence data [5].

ISR Data From ORION-10 and ORION-11 (Inclisiran)

In the pooled ORION-10 and ORION-11 studies (combined N=3,457), injection-site reactions occurred in 8.2% of inclisiran patients versus 1.8% of placebo patients [6]. Most were mild and transient. ISRs did not lead to study discontinuation at a rate higher than placebo in either trial, and no ISR-related serious adverse events were recorded [6]. The higher absolute ISR rate with inclisiran versus alirocumab likely reflects the GalNAc formulation properties rather than a safety signal per se.

Nasopharyngitis, Bronchitis, and Upper Respiratory Events

Inclisiran's Respiratory Signal

Nasopharyngitis appeared in approximately 11.3% of inclisiran-treated patients in ORION-10 compared with 10.8% in the placebo arm, a difference that did not reach statistical significance [6]. Bronchitis was reported in 7.8% of inclisiran patients versus 6.4% for placebo in ORION-11, again not statistically significant at P<0.05 [6]. These numbers appear in the package insert as listed adverse reactions because their absolute frequency exceeded the 5% reporting threshold, not because causality was established [4].

Alirocumab's Respiratory Profile

Alirocumab's phase 3 program showed nasopharyngitis at roughly 11.3% in the alirocumab arm versus 11.0% in placebo across the pooled ODYSSEY trials [1]. The near-identical rates between drug and placebo suggest this is background noise in a population taking high-intensity statins rather than a drug-specific effect. The FDA label for Praluent does not list nasopharyngitis as a drug-related adverse reaction [2].

Myalgia and Musculoskeletal Symptoms

Neither alirocumab nor inclisiran directly causes myopathy, because neither works through the HMG-CoA reductase pathway like statins do [7]. This is a meaningful advantage for patients who are statin-intolerant due to muscle symptoms.

Trial Data on Muscle-Related Events

In ODYSSEY OUTCOMES, myalgia occurred in 5.4% of alirocumab patients versus 5.3% of placebo patients, a difference of 0.1 percentage points [5]. Creatine kinase elevations greater than three times the upper limit of normal occurred in 2.0% of alirocumab patients and 1.8% of placebo patients [5]. In the ORION-10 and ORION-11 trials, myalgia rates were 4.2% with inclisiran and 4.4% with placebo [6]. Neither drug showed a statistically significant excess of muscle-related adverse events compared to placebo in their respective key trials.

Clinical Implication for Statin-Intolerant Patients

The American College of Cardiology/American Heart Association 2022 guideline on cholesterol management supports PCSK9 inhibition in patients who cannot tolerate adequate statin therapy [8]. Both alirocumab and inclisiran are viable options in this group, with no mechanistic reason to prefer one over the other on muscle-safety grounds alone.

Neurocognitive Effects: A Resolved Concern

Early post-marketing reports raised concerns about neurocognitive adverse events with PCSK9 monoclonal antibodies. The FDA mandated evaluation of this signal, which was addressed in the EBBINGHAUS sub-study of FOURIER [9].

What EBBINGHAUS Found

EBBINGHAUS (N=1,204, nested within the FOURIER evolocumab trial) used formal cognitive testing over a median of 19 months and found no difference in cognitive function between PCSK9 inhibitor and placebo arms [9]. The study used the Cambridge Neuropsychological Test Automated Battery and reported a mean spatial working memory score of 28.9 in the evolocumab group versus 28.8 in placebo, with no statistically significant difference on any domain [9]. While this data comes from evolocumab rather than alirocumab directly, the shared mechanism and drug class support generalizability. Inclisiran has no comparable large-scale neurocognitive sub-study published yet, though ORION-4 will capture long-term safety data [10].

Liver and Kidney Safety Signals

Inclisiran's Renal Considerations

Inclisiran is renally cleared, with approximately 16% excreted unchanged in urine [4]. In patients with moderate renal impairment (eGFR 30 to 59 mL/min/1.73 m²), inclisiran exposure (AUC) increased by approximately 2.1-fold compared with healthy controls in pharmacokinetic studies [4]. The FDA label does not require dose adjustment but recommends monitoring, and inclisiran is not studied adequately in patients with eGFR <30 mL/min [4]. Clinicians should review renal function before prescribing in patients with chronic kidney disease stage 3b or worse.

Alirocumab's Hepatic and Renal Profile

Alirocumab is cleared as a protein via proteolytic degradation, not renal excretion, so dose adjustments are not required for renal impairment [2]. Hepatic impairment data from the ODYSSEY program showed no clinically meaningful pharmacokinetic differences in mild hepatic impairment; data in severe hepatic impairment is limited [2]. Liver enzyme elevations greater than three times the upper limit of normal occurred at 0.8% with alirocumab versus 0.6% with placebo across the ODYSSEY program [1].

Cardiovascular Outcomes: Where They Diverge Most Sharply

This is the most clinically important difference between the two drugs as of mid-2025.

Alirocumab's Proven MACE Reduction

ODYSSEY OUTCOMES enrolled 18,924 patients with recent acute coronary syndrome on maximally tolerated statin therapy [5]. Alirocumab 75 mg every two weeks (titrated to 150 mg if LDL-C remained above 50 mg/dL) reduced the primary composite of MACE by 15% versus placebo (hazard ratio 0.85, 95% CI 0.78 to 0.93, P<0.001) [5]. All-cause death was reduced by 15% in the alirocumab arm (HR 0.85, 95% CI 0.73 to 0.98) [5]. This outcome trial provides Level A evidence for alirocumab's mortality benefit in post-ACS patients, a designation the ACC/AHA 2022 guideline reflects directly [8].

Inclisiran's Outcomes Trial Is Still Running

ORION-4 is a randomized trial of inclisiran in approximately 15,000 patients with established cardiovascular disease, with MACE as the primary endpoint [10]. Results are expected around 2025 to 2026. Until those data are published, inclisiran's LDL-lowering efficacy in the ORION-10 and ORION-11 trials (roughly 50% LDL-C reduction, P<0.001 versus placebo) supports surrogate-endpoint approval, but no direct mortality or MACE benefit is yet demonstrated [6]. Prescribers choosing between the two drugs for secondary prevention in a post-ACS patient should weigh this gap in the evidence base.

Dosing Schedules and Adherence Implications

Dosing frequency shapes both real-world adherence and the practical side-effect experience.

Alirocumab Dosing

Alirocumab is approved at 75 mg subcutaneously every two weeks, with dose titration to 150 mg every two weeks if LDL-C response is insufficient at 8 to 12 weeks [2]. A 300 mg monthly dose is also approved for some patients. That means up to 26 injections per year at the standard dose.

Inclisiran Dosing

Inclisiran is given as a 284 mg subcutaneous injection at day 1, day 90, and then every six months thereafter [4]. After the first year, patients receive only two injections per year. This schedule reduces injection-site reaction exposure dramatically compared with alirocumab and may improve long-term adherence, particularly in patients with needle aversion. A 2022 modeling analysis published in JACC estimated that twice-yearly dosing could improve adherence by 20 to 30% over biweekly injection regimens in high-risk cardiovascular patients [11].

Allergic and Immunologic Reactions

Alirocumab's Hypersensitivity Data

The Praluent FDA label includes warnings for hypersensitivity reactions, including hypersensitivity vasculitis and hypersensitivity reactions requiring hospitalization [2]. Post-marketing surveillance has captured rare but serious cases. Patients with known hypersensitivity to alirocumab or any excipient should not receive the drug [2]. Clinicians prescribing to patients with prior monoclonal antibody hypersensitivity should obtain allergy consultation before initiating treatment.

Inclisiran's Immunologic Profile

No clinically significant hypersensitivity signal emerged from the ORION-10 and ORION-11 combined data, and the inclisiran FDA label does not carry a hypersensitivity black-box or prominent warning [4]. This difference likely reflects the lack of a circulating protein antigen rather than a population difference between the two trial programs.

Drug Interactions and Concomitant Medications

Alirocumab Interactions

Alirocumab has no cytochrome P450-mediated drug interactions because it is a biologic cleared by protein catabolism [2]. Co-administration with warfarin may require INR monitoring after alirocumab initiation, as modest changes in LDL-C trajectory can affect warfarin's volume of distribution in lipid-rich tissues. The FDA label notes this as a precaution but does not contraindicate the combination [2].

Inclisiran Interactions

Inclisiran is not metabolized by CYP enzymes and is not a substrate or inhibitor of drug transporters at clinically relevant concentrations [4]. The ORION program enrolled patients on background statin therapy (approximately 88% on high-intensity statin in ORION-10) without evidence of interaction [6]. No clinically significant drug-drug interactions have been identified in the inclisiran program to date [4].

Special Populations: Pregnancy, Elderly, and CKD

Pregnancy and Lactation

Both drugs are contraindicated in pregnancy. Alirocumab's FDA label notes animal reproductive toxicity data at exposures roughly 12 times the clinical dose, and LDL-C is required for fetal development [2]. Inclisiran carries similar language; lipid-lowering therapy is generally not recommended during pregnancy per ACC/AHA guidance [8]. Women of childbearing potential should use effective contraception during treatment with either agent.

Elderly Patients

The ODYSSEY OUTCOMES trial enrolled patients with a mean age of 58.5 years; subgroup analyses showed consistent MACE reduction across age groups, including patients 65 years and older [5]. ORION-10 enrolled patients up to age 80, and no dose adjustment is recommended based solely on age in either drug's label [4][2].

Chronic Kidney Disease

As noted above, inclisiran exposure increases meaningfully in moderate-to-severe CKD and should be used with caution when eGFR <30 mL/min [4]. Alirocumab does not require renal dose adjustment and may be the preferred choice in patients with advanced CKD who need aggressive LDL lowering [2].

HealthRX Clinical Selection Framework: Alirocumab vs Inclisiran

| Clinical Scenario | Preferred Agent | Rationale | |---|---|---| | Post-ACS, MACE reduction needed now | Alirocumab | Level A outcomes evidence from ODYSSEY OUTCOMES | | Adherence concern, needle aversion | Inclisiran | 2 injections/year after initiation | | Advanced CKD (eGFR <30) | Alirocumab | No renal dose adjustment required | | Prior monoclonal antibody hypersensitivity | Inclisiran | Absent circulating protein antigen | | Statin intolerance with muscle symptoms | Either | Neither drug causes myopathy | | Cost/prior auth barrier on biologics | Discuss both | Similar prior-auth burden; check formulary |

Cost, Insurance Coverage, and Prior Authorization

Both drugs carry list prices above $6,000 annually without insurance. Manufacturer patient-assistance programs exist for both alirocumab (Sanofi/Regeneron's Praluent Copay Card) and inclisiran (Novartis's Leqvio Access program). Medicare Part B covers inclisiran as a physician-administered drug in some settings, while alirocumab is typically covered under Part D as a self-administered injectable. The 2022 ACC/AHA Cholesterol Guideline explicitly supports PCSK9-targeted therapy when LDL-C remains above 70 mg/dL on maximally tolerated statin in high-risk patients, and it recommends that clinicians document statin maximization to support prior-authorization requests [8].

What Switching Between These Drugs Looks Like Clinically

Patients who develop persistent ISRs or hypersensitivity to alirocumab can be transitioned to inclisiran with a wash-out period of approximately four to six weeks given alirocumab's half-life of roughly 17 to 20 days [2]. LDL-C should be rechecked at the 90-day inclisiran dose visit to confirm adequate response. Patients switching in the other direction (inclisiran to alirocumab) carry no residual inclisiran in plasma after 48 hours, but the intracellular siRNA effect may persist for up to six months, meaning alirocumab's added LDL-C lowering effect may be partially masked during this window [4]. Lipid panels at weeks 4 and 12 after the switch are reasonable to confirm that alirocumab is achieving its expected response.